RNA Extended Interventional Nucleic Acid (REINA) Longitudinal Study: Decreased Risk of CIN2+/CIN3+ With Low‐Grade Cytology After A Previous Negative HPV Test
Cytopathology · 2026-09 · 37 (5) · 531-537
DOI: 10.1111/cyt.70090 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cytopathology, online erschienen am 25.05.2026. Verfasst von Rosario Granados und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Hospital Universitario de Getafe, Madrid, Spain. Hauptthemen laut MEDLINE: Uterine Cervical Dysplasia, Human Papillomavirus Viruses, Papillomavirus Infections, Uterine Cervical Neoplasms. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The Foundation for Biomedical Research of the University Hospital of Getafe, Hologic, Inc, Hologic.
Abstract (Originalsprache)
Objective
To analyse the impact of a previous negative mRNA HPV test in the immediate and 6 year risk of developing CIN2+/CIN3+ lesions in women with low‐grade (LG, including ASC‐US and LSIL) cytology in the second round of cotest screening.
Methods
A prospective longitudinal study with LBC (ThinPrep, Hologic) and mRNA Aptima HPV test. Cotest was performed to 5053 asymptomatic women aged 25–65 years within an opportunistic screening programme in Madrid. Women with LG cytology, regardless of the mRNA HPV test result, were followed up (FU) to 10 years. The interventional arm ‘RNA‐based Extended Interventional Nucleic Acid (REINA)’ recruited 2000 women with negative results in the first round for a second cotest 4 years later, and were FU to 6 more years. The risk of a CIN2+/CIN3+ at 6 years after a first LG cytology was calculated.
Results
With an unknown HPV history, 18.7% of mRNA HPV‐positive women at first cotest had LG cytology. Their immediate CIN2+ and CIN3+ risks were 24.7% and 12.8%, respectively, increasing to 31.8% and 17.0% after a 6‐year FU. The long‐term incidence of CIN2+ was strongly associated with mRNA HPV infection ( p = 0.00001). From REINA, 20% of women with a new positive mRNA HPV result at second cotest had LG cytology, carrying much lower immediate and 6‐year cumulative CIN2/CIN3 risks (5.0% and 10.0% respectively).
Conclusions
A previous negative Aptima mRNA HPV test confers a protective effect for CIN2+/CIN3+ in mRNA HPV‐positive women with minor cytological changes. The adjusted risks impact patient management, decreasing colposcopy referrals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Hospital Universitario de Getafe, Madrid, Spain.
- Universidad Europea de Madrid, Facultad de Medicina, Salud y Deportes. Departamento de Medicina, Madrid, Spain.
- Department of Gynecology, Hospital Universitario de Getafe, Madrid, Spain.
Förderung
- The Foundation for Biomedical Research of the University Hospital of Getafe
- Hologic, Inc
- Hologic
Zitieren
APA
Granados, R., Duarte, J. A., Luján, D. R., Gutierrez-Pecharromán, A. M., Solís, I., Molpeceres, L., & Bajo, P. (2026). RNA Extended Interventional Nucleic Acid (REINA) Longitudinal Study: Decreased Risk of CIN2+/CIN3+ With Low‐Grade Cytology After A Previous Negative HPV Test. Cytopathology, 37(5), 531-537. https://doi.org/10.1111/cyt.70090
Vancouver
Granados R, Duarte JA, Luján DR, Gutierrez-Pecharromán AM, Solís I, Molpeceres L, et al. RNA Extended Interventional Nucleic Acid (REINA) Longitudinal Study: Decreased Risk of CIN2+/CIN3+ With Low‐Grade Cytology After A Previous Negative HPV Test. Cytopathology. 2026;37(5):531-537. doi:10.1111/cyt.70090
BibTeX
@article{Granados2026,
author = {Granados, Rosario and Duarte, Joanny A and Luján, David R and Gutierrez-Pecharromán, Ana M and Solís, Isabel and Molpeceres, Lourdes and Bajo, Paloma},
title = {RNA Extended Interventional Nucleic Acid (REINA) Longitudinal Study: Decreased Risk of CIN2+/CIN3+ With Low‐Grade Cytology After A Previous Negative HPV Test},
journal = {Cytopathology},
year = {2026},
volume = {37},
number = {5},
pages = {531--537},
doi = {10.1111/cyt.70090}
}
EUVIMED